<DOC>
	<DOCNO>NCT00344448</DOCNO>
	<brief_summary>This study examine effect drug Raptiva ( efalizumab ) patient Sj√∂gren 's syndrome ( SS ) , autoimmune disease affect gland produce saliva &amp; tear . The cause SS know , inflammation play important role . Raptiva approve Food Drug Administration treat psoriasis , inflammatory skin disease . Patients 18 year age &amp; old SS may eligible study . Candidates screen history &amp; physical examination , chest x-ray , oral &amp; eye examination . Participants randomly assign receive either Raptiva placebo ( inactive substance look like Raptiva ) first 3 month study . For next 3 month , participant receive Raptiva . Both Raptiva &amp; placebo inject skin week . Evaluation treatment &amp; 2 month treatment follow : Full comprehensive evaluation ( begin study , week 13 &amp; 25 2 month treatment end ) : - Physical examination &amp; blood draw . - Saliva collection do two way : 1 ) suction cup connect collection tube place salivary gland duct mouth tongue ; 2 ) sour-tasting liquid apply top &amp; side tongue 30-second interval stimulate saliva production . - Eye exam tear gland function . - Questionnaires mouth &amp; eye dryness , energy level overall well-being . - Lip biopsy ( screen &amp; week 13 visit ) . A minor salivary gland remove examination microscope . The low lip numb , small cut make inside lip , several gland remove . The cut close stitch remove 5 7 day . - Magnetic resonance image parotid gland ( salivary gland near ear ) week 1 , 13 25 . The patient lie stretcher move scanner ( metal cylinder contain strong magnetic field ) . The head hold place scan . The study last 90 minute . - Short evaluation week 3 , 5 , 9 , 15 , 17 , 21 1 month treatment end . - Medical history &amp; physical examination , blood draw , evaluation change symptom side effect , review current medication week 3 , 9 , 15 21 . - Laboratory test , evaluation change symptom side effect , review current medication , saliva collection without sour liquid short evaluation tear production week 5 17 . - Blood test week 29</brief_summary>
	<brief_title>Pilot Study Raptiva Treat Sjogren 's Syndrome</brief_title>
	<detailed_description>The LFA-1/ICAM-1 interaction important migration lymphocytes inflammatory site , T-lymphocyte activation , antigen presentation , maintain integrity immunologic synapse . In murine human Sjogren 's Syndrome , increase expression LFA-1 find activate lymphocyte , increased expression ICAM-1 present activate endothelial cell diseased salivary lacrimal gland . In animal model , blockade LFA-1/ICAM-1 interaction result reduction glandular inflammation . Raptiva ( efalizumab ) recombinant humanize monoclonal antibody bind human CD11a , alpha-subunit Leukocyte Function Antigen-1 ( LFA-1 ) inhibit LFA-1/ICAM-1 interaction . Raptiva FDA-approved medication treatment mild-to-moderate psoriasis . In pilot , proof concept , randomize , double-blind , placebo-controlled study , 25 patient Sjogren 's syndrome may enrol . In first , double-blind phase study , patient randomize treated weekly subcutaneous ( SC ) injection either Raptiva ( 1mg/kg ) placebo 12 week . In second open label phase , patient treat weekly SC injection Raptiva ( 1mg/kg ) another 12 week follow additional 8 week . Safety evaluate use standard clinical laboratory parameter . To assess potential effect Raptiva Sjogren 's syndrome , minor salivary gland biopsy , oral ocular evaluation , measurement surrogate marker inflammation compare Raptiva placebo treat group treatment . Patients either tolerate drug worsen disease activity withdrawn protocol . If Raptiva well tolerate study treatment associate improvement clinical parameter Sjogren 's Syndrome , large study efficacy plan .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA : Up 25 patient may enrol study obtain least 20 patient complete study allow estimate 20 % early attrition rate . Eligible patient primary SS diagnose accord AmericanEuropean Consensus Group Sjogren 's Syndrome Classification Criteria . Subjects choose base potential capacity reverse inflammatory process least partially recover exocrine function salivary lacrimal gland , indicate inclusion criterion require minimal level salivary flow marker functional gland tissue . Prescreening , would include ophthalmologic evaluation , standard laboratory test , minor salivary gland biopsy , perform natural history protocol , eligible patient offer sign inform consent protocol . Age entry least 18 year Must give write informed consent prior entry protocol . Must fulfill least 4 6 follow criterion Primary SS define AmericanEuropean Consensus Group Sjogren 's Syndrome Classification Criteria , include either item IV VI , fulfill 3 4 objective criterion ( III , IV , V , VI ) [ 53 ] : Ocular symptom ( least one ) : Dry eye great 3 month Foreign body sensation eye Use artificial tear great 3x/day Oral symptom ( least one ) : Dry mouth great 3 month Swollen salivary gland Need liquid swallow dry food Ocular sign ( least one ) : Schirmer test ( without anesthesia ) less equal 5 mm/5 min Positive vital dye staining ( van Bijsterveld great equal 4 ) Histopathology : Minor salivary gland biopsy show focal lymphocyte sialoadenitis ( focus score great equal 1 per 4 mm ( 2 ) ) Oral sign ( least one ) : Unstimulated whole salivary flow ( less equal 1.5 ml 15 min ) Abnormal parotid sialography Abnormal salivary scintigraphy Autoantibodies ( least one ) : AntiSSA AntiSSB One following : Serum ANA level great equal 1EU Serum AntiSSA level great equal 20EU Serum AntiSSB level great equal 20EU Serum RF level great equal 20 IU/ml One following : ESR great 25 mm/hr men ; ESR great 42 mm/hr woman Serum IgG level great equal 1750 mg/dl Serum CRP level great equal 0.8 mg/dl Stimulated salivary flow least 0.1 ml/min . Minor salivary gland biopsy focus score great equal 4 within 12 month prior study enrollment . Score 3 Oxford scale least one eye study entry . Negative age gender appropriate malignancy screen breast , cervical , colorectal cancer woman ; prostate colorectal cancer men . Specifically : All woman : pelvic exam Papanicolaou smear within one year study entry . Women age 40 older : mammogram within 1 year study entry , Both gender age 50 old ; stool screen occult blood within one year , flexible sigmoidoscopy colonoscopy within five year Men age 50 older : rectal examination prostate specific antigen test EXCLUSION CRITERIA : Past head neck irradiation . Hepatitis B , C , HIV , HTLV infection . History lymphoma monoclonal gammopathy unknown significance ( MGUS ) . Sarcoidosis . Graftversushost disease . Women childbearing potential require negative pregnancy test screening . Women childbearing potential fertile men practice unwilling practice birth control period three month completion study . Any therapy human murine antibody experimental therapy within 3 month . Therapy cyclophosphamide , pulse methylprednisolone IVIg , azathioprine , mycophenolate mofetil , oral cyclosporine methotrexate within 4 week first study treatment . History rituximab therapy . Prednisone dose great equal 10 mg/day . Allergy murine human antibody . History anaphylaxis . Serum creatinine great 2.0 mg/dl . History malignancy . Active infection require use intravenous antibiotic resolve within 1 week Day 1 . Any active viral infection resolve within 10 day prior Day 1 . WBC le 2000/microL ANC less 1500/microL Hgb less 9.0 g/dL platelet le 150,000/microL absolute lymphocyte count less equal 500/microL . ALT and/or AST great 1.5x upper limit normal ( ULN ) alkaline phosphatase great 1.5x ULN . Significant concurrent medical condition , opinion Principal Investigator , could affect patient 's ability tolerate complete study . Live vaccine within 12 week first treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Adhesion Molecule</keyword>
	<keyword>Interventional Study</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Sjogren Syndrome</keyword>
	<keyword>SS</keyword>
</DOC>